Thursday, Biogen Inc. (BIIB) announced compelling topline results from the Phase 2 CELIA study evaluating diranersen in participants with early Alzheimer's disease.
Notably, the study did not meet its primary endpoint assessing dose response for change from baseline on the Clinical Dementia Rating-Sum of Boxes at Week 76.
However, these results provide the first evidence from a randomized Phase 2 study of a tau-directed therapy demonstrating both robust biomarker impact and cognitive benefit in early Alzheimer's disease.
The company stated that the pre-specified analyses of cognitive endpoints showed slowing of clinical decline across all studied doses, particularly in participants receiving the lowest dose of diranersen, 60 mg administered every 24 weeks.
Diranersen also demonstrated robust reductions in both cerebrospinal fluid tau and tau pathology across all studied doses, with reductions maintained throughout the dosing period.
In the pre-market hours, BIIB is trading at $216.11, up 5.66 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.